Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 3
- Collinridge GL Peineau S Howland JG Wang YT Nat. Rev. Neurosci 2010 11 459 20559335
- 10.1016/0306-4522(95)00259-L · DOI · Paper page
- Machado-Vieira R Ibrahim L Henter ID Zarate CA Jr Pharmacol. Biochem. Behav 2012 100 678 21971560 PMC3253881 · DOI · Paper page
Cited by
Items 1,601–1,640 of 1,640
Cheung, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1855963
Kim, Y., Jang, S., Kang, H., Kim, J., Kang, E. S., Kong, S., Park, J.-H., Cheon, S., Oh, Y. H., Kang, M., et al. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e314
Guo, Z., Chen, P., Chen, G., Qi, Z., Jia, Y., Tao, Q., & Wang, Y. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.08.038
Kočović, D. M., Momčilović, S., & Svetozarević, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167242 · Cited by 1
“As a result, chronic stress is associated with reduced serotonergic transmission and altered receptor expression, which is strongly implicated in the pathophysiology of major depressive and anxiety disorders [90].”
He, J., Zhu, S., Luo, J., & Ou, J. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1871297
History of Anesthesia Therapeutics
Liu, H., & Kaye, A. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_1
New Developments in Anesthetic Mechanism Research
Deng, J., & Zuo, Z. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_2
Zhang, L.-L., Wang, X.-W., Cheng, Y.-D., Ya, L., El-Seedi, H. R., Sun, P.-C., He, W.-B., Zhang, J.-J., & Zhai, Z.-G. (2026) · Journal of Natural Medicines · doi:10.1007/s11418-026-02067-w · Cited by 1
“The hippocampus primarily facilitates learning, memory integration, and stress response processes, operating largely independently from the PFC pathways responsible for rapid emotional regulation [34, 35 ].”
Kavuran, İ. B., Önalan, E., Turk, Z. I., & Eröksüz, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1910199
Cobrotoxin alleviates lipopolysaccharide-induced depression-like behavior in mice
Qian, J., Lou, J., Liu, K., Liu, W., Yang, S., Xiang, T., & Qin, Z.-H. (2026) · Toxicon · doi:10.1016/j.toxicon.2026.109276
Yu, Q., Zhou, L., Li, Q., Cao, K., Yang, L., Ye, M., Shi, Y., Deng, D., & Zhang, R. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158751
Regional cerebral blood flow correlates with transcriptional and cellular signatures in tinnitus
Luan, J., Chen, Y., Yang, A., Xu, M., Yu, H., Wang, Y., Shu, N., Ouyang, G., Yuan, Z., & Ma, G. (2026) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-026-10549-6
Xu, Y., Du, J., Li, X., Diao, H., Nie, L., Yuan, C., Li, J., & Wang, Y. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03833-8
Magray, M. N. Z., Taufiq, L., Bari, S., & Naz, N. (2026) · Nutritional Neuroscience · doi:10.1080/1028415x.2026.2718400
Bae, J., Lee, J., Song, S., Jeong, K., Frankiv, N., Park, C., Hwang, C. Y., Kim, Y. K., Yu, B.-Y., & Im, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.24.745657
Verma, A. K., Mori, H., Roy, B., & Dwivedi, Y. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1922816
“Convergent evidence further indicates that transcriptome-wide alterations in gene expression are central to aberrant synaptic plasticity in the depressed brain (Duman and Aghajanian, 2012; Duric et al., 2013; Price and Duman, 2020; Yoshino et al., 2021).”
Wang, Y., Karaca, S. C., Rasmussen, M. D., Kristensen, J. L., & Kohlmeier, K. A. (2026) · Neuroscience · doi:10.1016/j.neuroscience.2026.08.049
Psilocibina e neuroplasticidade: novas perspectivas terapêuticas para depressão resistente
Castro, L. A., Júnior, A. L. A. S., Simões, G. G. C., de Souza, V. R. S., Pereira, L. L. M. D., Lacerda, A. L. D. S., & da Silva, C. L. (2026) · Vértices · doi:10.19180/1809-2667.v28n22026.23658
Jia, X., Gong, Q., Xiong, B., Hu, Y., Ali, T., Zheng, C., Wei, S., Huang, J., Wang, Z., Feng, J., et al. (2026) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2026.106988
周喜丹, Li, S., Guo, C., Wu, S., Wu, X., Wu, M., Wu, C., Li, K., Cui, Y., & Zhou, T. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03840-9
Wang, J., Lin, Y., Zhang, T., Xu, P., Lei, S., Yang, H., & Chen, Z. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71144
The Neurocognitive Benefits of Martial Arts
Kayale, F. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1015479
Barlattani, T., Sernia, G., D’Amelio, C., Maritato, S., Gabriele, D., Bologna, A., Trebbi, F., Ricci, V., Tomasetti, C., Martiadis, V., et al. (2026) · Psychiatry International · doi:10.3390/psychiatryint7050207
Neural networks and brain plasticity
Ghosh, S., Singh, K. K., & Sinha, J. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36544-7.00012-4 · Cited by 10
de Faria, D. A., Freire, V. A. F., Marques, D. G. D. M., da Fonseca, P. H. N., Santos, K. D. F., de Oliveira, C. B., Perucci, L. O., Pinheiro, M. B., & Barros-Pinheiro, M. (2026) · Archives of Women s Mental Health · doi:10.1007/s00737-026-01752-9
“Additionally, physical activity promotes the pro-neurogenic effects of progenitor cells in the hippocampus (Eyre and Baune 2012), which may contribute to improvements in depression and anxiety (Brooker et al. 2017; Duman and Aghajanian 2012; Cotman, Berchtold and Christie 2007).”
Elliott, B. B., Prasad, V. V., Taylor, A., Shofner, I., Kerns, K. C., Meyer, J., & McNeill, E. M. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1910088
Ketamine attenuates habenula activity in response to aversive outcomes during Pavlovian learning
Pulcu, E., Costi, S., Hortelano, P. A., Wigg, C., Hamilton, S., Martens, M., Lawson, R. P., McShane, R. H., Cowen, P., Murphy, S. E., et al. (2026) · Current Biology · doi:10.1016/j.cub.2026.08.044 · Cited by 2
Hamada, F., Hori, H., Kumagai, H., Ogata, M., Yokoyama, H., Tomiyama, Y., Sugawara, H., Asada, R., Hatanaka, A., Masuda, M., et al. (2026) · Metabolites · doi:10.3390/metabo16090679
“Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor-A (VEGF-A), which regulate neuroplasticity, neurogenesis, angiogenesis, and neurovascular coupling, have also been associated with cognitive performance and functional outcomes in BD [18,19].”
Hou, X., Wang, H., Liu, R., Zhang, F., Lu, Q., Zhang, Y., Zhou, Y., Liu, Y., Zhou, J., Li, H., et al. (2026) · Psychological Medicine · doi:10.1017/s0033291726105571
“The prefrontal cortex is involved in top-down regulation of affective and behavioral responses, whereas the hippocampus is highly sensitive to stress-related plasticity and has also been implicated in sleep-related dysfunction in depression (Duman & Aghajanian, 2012).”
Wolfson, P., & Carroll, C. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1886833
“…that ketamine ’ s more durable effects are mediated by a burst of activity-dependent synaptic plasticity: the glutamate surge following GABAergic disinhibition activates AMPA receptors and downstream BDNF-TrkB and mTORC1 signaling, driving rapid synaptogenesis in prefrontal circuits (41 – 43).”
Sun, X.-R., Chen, Y.-X., Zhang, X.-J.-L., Jiang, N., Liu, X., Chang, Q., & Pan, R.-L. (2026) · Behavioral and Brain Functions · doi:10.1186/s12993-026-00360-y
“Synaptic architecture and neurotransmitter homeostasis are central to affective pathology [50–52].”
Metelska, A., Ziemichód, W., & Karakuła‐Juchnowicz, H. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16100488
Hsu, T., Chu, T.-H., Lee, M. T., Peng, W.-H., Wu, C., Lee, Y., Teng, Y.-N., & Ho, Y. (2026) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2026.174273
Malewska-Kasprzak, M., Rybakowski, F., & Dmitrzak‐Węglarz, M. (2026) · CNS Spectrums · doi:10.1017/s1092852926101187
Tuberostemonine produces antidepressant effects via the BDNF/TrkB/Erk/CREB signaling pathway
Chen, F., Li, L., Xu, X., Meng, Z., Yu, Q., Chen, L., Ai, Q., Deng, Y., Wei, J., Liang, G., et al. (2026) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2026.118064
Iskakova, D. M., İlçe, B. Y., Kamzanova, A. T., Sitakanova, A., Hamoudi, R., & Kustubayeva, A. (2026) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2026.1904444
Lin, M., Lin, M., & Dong, J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03888-7
Zhang, J., Ma, Y., Lu, M., Jiang, X., Zhong, Q., Zhang, Y., Xiong, Y., Wu, Q., Chen, L., & Pang, R. (2026) · PLoS ONE · doi:10.1371/journal.pone.0359940
“Beyond individual targets, our GO and KEGG enrichment analyses revealed that the overlapping genes are significantly enriched in neural synaptic function, neurotransmitter binding, and the neuroactive ligand-receptor interaction pathway—all of which are central to depression pathogenesis [62,67–69].”
Wzorek, A., Ono, T., Klika, K. D., Baecker, D., Zhang, W., Moriwaki, H., & Soloshonok, V. A. (2026) · Ukrainian Chemistry Journal · doi:10.33609/2708-129x.92.6.2026.21-33
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.